Loading…
← CockpitCompetitor Analysis › 0512.HK Grand Pharmaceutical Group LimitedOpen in the cockpit ↗

Grand Pharmaceutical Group Limited0512.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major

Hong Kong-listed Chinese drugmaker: nuclear-medicine cancer therapies, critical-care and respiratory drugs, ophthalmology and heart-brain emergency medicines.

Momentum weak 37
Mkt cap
$1.93B
US dollars, full cap
Free float
35%
of shares outstanding
$/day
$1.83M
20-day average traded
Fwd P/E
9.4×
forward earnings
ROIC−WACC
-1.1 pp
WACC 7.7%
Hurdle
-13 pp
Req g minus delivered
Next earnings
119 days
17 Mar 2027
Close · HKDHK$4.29
1D-0.6%
1W-1.8%
1M-8.1%
3M-18.4%
6M-24.6%
YTD-45.4%
1Y-49.5%
ATR %3.3%
52w lowhigh51.5% off high

What Grand Pharmaceutical does

Hong Kong-listed Chinese drugmaker: nuclear-medicine cancer therapies, critical-care and respiratory drugs, ophthalmology and heart-brain emergency medicines.

Sells prescription drugs for emergency, critical-care, respiratory and eye conditions to hospitals, where older products face government bulk-purchase price cuts. Its growth push is nuclear medicine, radioactive cancer treatments, led by yttrium-90 microspheres already on sale, with in-house radioligand drugs in trials.

Products and services

  • Pharmaceutical technology segment (respiratory, critical-car
  • Biotechnology segment
  • Nuclear-medicine anti-tumor (yttrium-90 microspheres, radiol

Customers

  • Hospitals
  • Pharmacies and distributors

Where it sits in the supply chain

  • Pharmaceuticals
  • Specialty drugs and nuclear medicine
  • Branded hospital drugs and…

What could go right

  • Nuclear-medicine anti-tumor growth
  • Late-stage in-house nuclear drugs and sepsis candidate

What could go wrong

  • Volume-based procurement price cuts
  • Clinical-trial and regulatory risk

Moat: narrow (IP / patents, regulatory licence). Licensed specialty drugs and a scarce nuclear-medicine franchise; older products face procurement pricing pressure.

Headquarters: Wuhan, China · Employees: 12,614

Named competitors

Grand Pharmaceutical at a glance

Size Grand Pharmaceutical (0512.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $1.93B, the 415th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$4.29 on 18 Nov 2026.

Performance Over six months the shares fell 24.6%, against -5.5% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 5th lowest of 21 in its peer set.

Growth Revenue grew 7.3% over the last twelve months (peer median +11.1%); the operating margin is 13.3% (peer median 20.9%).

Valuation It trades at 9.4× forward earnings against a peer median of 22.8× (2nd cheapest of 17).

Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -13 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.1 points below its cost of capital (7.7% WACC).

Next results Next results expected around 17 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 930512.HK 77
Six months, rebased to 100: Grand Pharmaceutical against the median of its 20 peers (local-currency closes).

Grand Pharmaceutical financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$12.6BHK$12.3BHK$11.6BHK$10.5BHK$9.56B
Revenue growth—+5%+11%+10%—
Gross profitHK$6.55BHK$6.78BHK$6.74BHK$6.52BHK$5.95B
EBITDAHK$2.32BHK$2.13BHK$2.55BHK$3.06BHK$2.91B
Net incomeHK$1.13BHK$1.24BHK$2.47BHK$1.88BHK$2.08B
Free cash flowHK$838MHK$774MHK$1.14BHK$1.73BHK$1.26B
Capital expenditureHK$1.50BHK$1.52BHK$678MHK$498MHK$1.67B
Total debtn/aHK$4.72BHK$4.44BHK$3.40BHK$4.48B

Quarterly statements and history in the cockpit →

Grand Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-10%0%+10%+20%4540600201SHILPAMEDHRMYONESOURCEBHVNALIVUSPFIZER300009600211ERISCOHANCE0009089969009420DMP3004366034566037073005730512.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Grand Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%50×100×4540600201SHILPAMEDHRMYONESOURCEALIVUSPFIZER300009600211ERISCOHANCE99696037070512.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Grand Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%100%200%300%600201HRMYPFIZER3000099969DMP0512.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Grand Pharmaceutical is the large dot.

Grand Pharmaceutical competitors and peer comparison

Head to head with its named competitors (0512.HK vs 0867.HK vs 3692.HK vs BSX)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Grand Pharmaceutical 0512.HK$1.93B-25%+7%13%9.4×1.2%
China Medical System 0867.HK$2.95B-15%+15%20%9.8×1.1%
Hansoh Pharma 3692.HK$25.3B-3%+25%38%25.8×7.9%
Boston Scientific BSX$63.3B-23%+9%21%14.1×5.8%

How Grand Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Grand Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure0512.HKPeer medianRank in peer set
1-month return-8.1%+1.7%6th lowest of 21
6-month return-24.6%-5.5%5th lowest of 21
Distance from 52-week high-51.5%-28.8%2nd lowest of 21
Revenue growth (TTM)+7.3%+11.1%7th lowest of 20
Operating margin13.3%20.9%7th lowest of 20
Forward P/E9.4×22.8×2nd cheapest of 17
Growth the price implies (Req g, 7 yrs)1.2%5.3%5th least demanding of 13
Growth delivered (Del g)+14.1%+12.5%7th highest of 13
Hurdle (Req g minus delivered)-12.8 pp-6.3 pp6th least demanding of 13
ROIC minus cost of capital-1.1 pp+1.6 pp9th lowest of 20
EV / EBITDA8.2×17.8×4th cheapest of 10
Net debt / EBITDA1.6×1.1×5th most indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Grand Pharmaceutical 0512.HKHong Kong$1.93B-25%+7%13%9.4×1.2%+14.1%
Tsumura & 4540.TJapan$1.93B+6%+13%18%10.4×n/an/a
Jinyu Bio-Technology 600201.SSChina$1.93B-21%+22%10%59.0×23.4%-2.5%
Shilpa Medicare SHILPAMED.NSIndia$1.91B+94%+37%21%54.3×n/an/a
Harmony Biosciences HRMYUnited States$1.94B+6%+20%22%8.6×-10.5%+40.3%
OneSource Specialty Pharma ONESOURCE.NSIndia$1.95B-14%+11%6%44.6×n/an/a
Biohaven BHVNUnited States$1.95B+46%n/an/an/an/an/a
Alivus Life Sciences ALIVUS.NSIndia$1.90B+36%+8%31%23.8×20.1%+6.2%
Pfizer PFIZER.NSIndia$1.88B-20%+12%34%21.9×11.2%+2.4%
Anhui Anke Biotechnology (Group) 300009.SZChina$1.88B-12%-9%30%18.1×8.0%+9.3%
Tibet Rhodiola Pharmaceutical 600211.SSChina$1.87B-8%+13%27%12.5×-1.2%+16.7%
Eris Lifesciences ERIS.NSIndia$1.98B0%+11%26%27.9×26.3%+20.9%
Cohance Lifesciences COHANCE.NSIndia$1.87B+7%+14%2%96.3×n/an/a
CSPC Hunan Jingfeng Pharmaceutical 000908.SZChina$1.85B-38%+5%-18%n/an/an/a
InnoCare Pharma 9969.HKHong Kong$2.01B-10%+146%35%32.2×-2.0%+341.1%
Hanall Biopharma 009420.KSSouth Korea$2.01B+12%+5%3%n/an/an/a
Dermapharm DMP.DEGermany$1.85B-29%+2%21%13.2×-3.4%+8.0%
Fujian Cosunter Pharmaceutical 300436.SZChina$2.02B-45%0%-47%n/an/an/a
Zhejiang Jiuzhou Pharmaceutical 603456.SSChina$2.03B+19%-1%14%16.9×1.7%+15.7%
Nanjing King-friend Biochemical Pharmaceutical 603707.SSChina$2.03B-3%+9%14%25.9×5.1%+6.4%
Shenyang Xingqi Pharmaceutical 300573.SZChina$1.83B-25%+17%33%13.0×5.4%+29.1%

Questions

Who are Grand Pharmaceutical's main competitors?
Named competitors: China Medical System (0867.HK), Hansoh Pharmaceutical (3692.HK), Boston Scientific (BSX). The cockpit's measured peer set (industry) also includes Tsumura & (4540.T), Jinyu Bio-Technology (600201.SS), Shilpa Medicare (SHILPAMED.NS), Harmony Biosciences (HRMY), OneSource Specialty Pharma (ONESOURCE.NS), Biohaven (BHVN).
Is Grand Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 9.4× against a peer median of 22.8×, 2nd cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -13 pp: the price already allows for a slowdown.
How has Grand Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -24.6% against -5.5% for the median peer; over one year -49.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.